Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | NQO2 | P16083 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.52 |
| ▸ | APP | P05067 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TTR | P02766 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470614 | 1.00 | MAOB (0.61) | MAOBMAOAPTGS1ACENQO2 | |
| SCHEMBL6470616 | 1.00 | MAOB (0.61) | MAOBMAOAPTGS1ACENQO2 | |
| SCHEMBL6469970 | 0.86 | PPARG (0.53) | MAOBMAOAPTGS1NQO2ALOX5 | |
| SCHEMBL919514 | 0.86 | PPARG (0.53) | MAOBMAOAPTGS1NQO2ALOX5 | |
| SCHEMBL918449 | 0.86 | AHR (0.54) | MAOBMAOAPTGS1ALOX5PTGS2 | |
| SCHEMBL6468964 | 0.86 | AHR (0.54) | MAOBMAOAPTGS1ALOX5PTGS2 | |
| SCHEMBL6468960 | 0.86 | AHR (0.54) | MAOBMAOAPTGS1ALOX5PTGS2 | |
| SCHEMBL18648480 | 0.86 | LCK (0.61) | PTGS1NQO2LCKALOX5APP | |
| SCHEMBL6469429 | 0.85 | LCK (0.54) | MAOBMAOAPTGS1NQO2LCK | |
| SCHEMBL918682 | 0.85 | LCK (0.54) | MAOBMAOAPTGS1NQO2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554236-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | Welichem Biotech Inc. (CA) | 2005-07-20 | — | — | EP | claimed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | claimed |
| WO-2004031117-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | WELICHEM BIOTECH INC. (CA) | 2004-04-15 | — | — | WO | claimed |
| US-7868047-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | WELICHEM BIOTECH INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| EP-1554236-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | Welichem Biotech Inc. (CA) | 2005-07-20 | — | — | EP | disclosed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2004031117-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | WELICHEM BIOTECH INC. (CA) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | NFKBIA, IKBKB, IKBKE | MAOB 2270/4885MAOA 3701/4885PTGS1 275/4885 |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | LTK, MMP8, CHUK | MAOB 3136/4885MAOA 4374/4885PTGS1 430/4885 |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | CHUK, MAP3K8, MAP3K1 | MAOB 3015/4885MAOA 4057/4885PTGS1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.